Actinium Pharmaceuticals (ATNM)
:ATNM
Want to see ATNM full AI Analyst Report?
Top Page
Actinium Pharmaceuticals
(ATNM)
Select Model
Select Model
Rating:42Neutral
Price Target:
$0.98
▼(-24.69% Downside)
Action:Reiterated
Date:06/19/26
The score is held down primarily by weak financial performance (ongoing losses, cash burn, and shrinking equity) and negative technical conditions (below key moving averages with bearish MACD). Corporate events add meaningful risk due to NYSE compliance/delisting uncertainty, while valuation offers limited support given a negative P/E and no dividend.
Positive Factors
Radioconjugate Platform Progress
The company advances a differentiated radioconjugate platform (ATNM-400, Actimab-A, Iomab-ACT) with new preclinical data across indications. A broad, science-driven pipeline increases the chance of durable value creation via partnerships or multiple clinical readouts over time.
Negative Factors
Persistent Cash Burn
Negative operating and free cash flow indicate the company must repeatedly access external capital to fund operations. Over months to years this raises dilution risk, constrains R&D sequencing, and increases dependency on successful financings or partnerships to sustain development.
Read all positive and negative factors
Positive Factors
Negative Factors
Radioconjugate Platform Progress
The company advances a differentiated radioconjugate platform (ATNM-400, Actimab-A, Iomab-ACT) with new preclinical data across indications. A broad, science-driven pipeline increases the chance of durable value creation via partnerships or multiple clinical readouts over time.
Read all positive factors
Actinium Pharmaceuticals (ATNM) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$32.32M
Dividend YieldN/A
Average Volume (3M)208.30K
Price to Earnings (P/E)―
Beta (1Y)1.94
Revenue GrowthN/A
EPS Growth48.96%
CountryUS
Employees31
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.75
Shares Outstanding31,374,990
10 Day Avg. Volume380,172
30 Day Avg. Volume208,296
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)5.42
Price to Sales (P/S)471.40
P/FCF Ratio-1.72
Enterprise Value/Market Cap-0.27
Enterprise Value/Revenue-95.67
Enterprise Value/Gross Profit-17.75
Enterprise Value/Ebitda0.38
Forecast
1Y Price Target
$6.00Price Target Upside361.54% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.85
Revenue Forecast (FY)N/A
Actinium Pharmaceuticals Business Overview & Revenue Model
Company Description
Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing and commercializing treatments, primarily focusing on those for bone marrow transplant (BMT) or other cellular and adoptive cell therapies. Its leadi...
How the Company Makes Money
null...
Actinium Pharmaceuticals Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
46
Neutral
Cash Flow
22
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Mar 2023 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 90.00K | 90.00K | 0.00 | 81.00K | 1.03M | 1.14M |
| Gross Profit | 485.00K | 90.00K | -811.00K | 81.00K | 1.03M | 620.00K |
| EBITDA | -22.64M | -33.07M | -37.43M | -48.03M | -32.32M | -24.25M |
| Net Income | -23.47M | -33.89M | -38.24M | -48.82M | -33.02M | -24.77M |
Balance Sheet | ||||||
| Total Assets | 45.44M | 51.77M | 76.90M | 81.44M | 114.19M | 80.39M |
| Cash, Cash Equivalents and Short-Term Investments | 42.13M | 48.00M | 72.90M | 76.68M | 108.91M | 77.83M |
| Total Debt | 1.52M | 1.69M | 1.57M | 2.11M | 2.58M | 310.00K |
| Total Liabilities | 43.13M | 43.94M | 44.14M | 45.07M | 47.71M | 6.84M |
| Stockholders Equity | 2.30M | 7.83M | 32.76M | 36.38M | 66.48M | 73.55M |
Cash Flow | ||||||
| Free Cash Flow | -22.98M | -24.68M | -33.08M | -47.49M | 8.28M | -21.00M |
| Operating Cash Flow | -22.88M | -24.58M | -33.07M | -47.34M | 8.64M | -20.87M |
| Investing Cash Flow | -106.00K | -104.00K | -11.00K | -153.00K | -366.00K | -133.00K |
| Financing Cash Flow | -218.00K | -217.00K | 29.32M | 14.87M | 23.11M | 35.22M |
Actinium Pharmaceuticals Technical Analysis
Negative
1.30
Price Trends
1.18
Negative
1.16
Negative
1.32
Negative
Market Momentum
-0.05
Positive
41.28
Neutral
20.07
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ATNM, the sentiment is Negative. The current price of 1.3 is above the 20-day moving average (MA) of 1.10, above the 50-day MA of 1.18, and below the 200-day MA of 1.32, indicating a bearish trend. The MACD of -0.05 indicates Positive momentum. The RSI at 41.28 is Neutral, neither overbought nor oversold. The STOCH value of 20.07 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ATNM.
Actinium Pharmaceuticals Risk Analysis
Actinium Pharmaceuticals disclosed 66 risk factors in its most recent earnings report. Actinium Pharmaceuticals reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Actinium Pharmaceuticals Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | $80.19M | ― | -201.43% | ― | ― | 33.86% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
43 Neutral | $266.60M | -2.66 | -94.90% | ― | ― | ― | |
42 Neutral | $32.32M | -1.37 | -218.67% | ― | ― | 48.96% | |
42 Neutral | $182.90M | -40.99 | -131.18% | ― | ― | -36.64% |
* Healthcare Sector Average
ATNM
Actinium Pharmaceuticals
1.03
-0.47
-31.33%
IFRX
InflaRx
1.81
1.02
127.67%
GANX
Gain Therapeutics
1.88
0.11
6.21%
UNCY
Unicycive Therapeutics
6.85
0.51
8.04%
ANL
Adlai Nortye Ltd. Sponsored ADR
10.10
8.63
587.07%
JUNS
Jupiter Neurosciences, Inc.
0.24
-0.87
-78.56%
Actinium Pharmaceuticals Corporate Events
Delistings and Listing ChangesRegulatory Filings and Compliance
Actinium Submits NYSE Compliance Plan to Restore Listing
Negative
Jun 18, 2026
On June 18, 2026, Actinium Pharmaceuticals submitted a compliance plan to the NYSE American after receiving notice on May 27, 2026, that it was not meeting continued listing standards related to minimum stockholders’ equity. The plan outline...
Business Operations and StrategyDelistings and Listing ChangesFinancial DisclosuresRegulatory Filings and Compliance
Actinium Highlights New ATNM-400 Data Amid Listing Pressure
Negative
May 29, 2026
On May 27, 2026, Actinium Pharmaceuticals disclosed that it had fallen out of compliance with NYSE American listing standards after reporting stockholders’ equity of about $2.3 million as of March 31, 2026 and losses in each of the last five...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.